Shares of Advaxis, Inc. (NASDAQ:ADXS) hit a new 52-week low during mid-day trading on Thursday . The company traded as low as $0.39 and last traded at $0.39, with a volume of 4862 shares changing hands. The stock had previously closed at $0.41.
A number of analysts have issued reports on ADXS shares. HC Wainwright reissued a “buy” rating on shares of Advaxis in a research report on Wednesday, September 12th. ValuEngine raised Advaxis from a “hold” rating to a “buy” rating in a research report on Thursday, November 1st.
The stock has a market capitalization of $20.82 million, a price-to-earnings ratio of -0.16 and a beta of 2.46.
In related news, Director Roni Appel acquired 33,333 shares of the business’s stock in a transaction dated Tuesday, September 11th. The shares were acquired at an average price of $1.20 per share, with a total value of $39,999.60. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 7.21% of the stock is currently owned by corporate insiders.
Several hedge funds have recently modified their holdings of the stock. LMR Partners LLP acquired a new position in shares of Advaxis during the second quarter worth $171,000. Paloma Partners Management Co acquired a new position in shares of Advaxis during the second quarter worth $265,000. Finally, Renaissance Technologies LLC grew its stake in shares of Advaxis by 173.0% during the third quarter. Renaissance Technologies LLC now owns 1,191,846 shares of the biotechnology company’s stock worth $1,120,000 after purchasing an additional 755,352 shares in the last quarter. Hedge funds and other institutional investors own 24.81% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This piece was first posted by Community Financial News and is the property of of Community Financial News. If you are accessing this piece on another website, it was illegally stolen and republished in violation of international trademark & copyright laws. The legal version of this piece can be viewed at https://www.com-unik.info/2018/12/08/advaxis-adxs-hits-new-12-month-low-at-0-39.html.
Advaxis Company Profile (NASDAQ:ADXS)
Advaxis, Inc, a clinical stage biotechnology company, focuses on the discovery, development, and commercialization of Listeria monocytogenes (Lm) technology based immunotherapies in the United States. It is developing Axalimogene filolisbac and ADXS-Dual that are Lm-LLO immunotherapy product candidates for the treatment of human papilloma virus associated cancers, including cervical, and head and neck cancers.
Featured Article: What is a Futures Contract?
Receive News & Ratings for Advaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis and related companies with MarketBeat.com's FREE daily email newsletter.